I received a promotional eletter this AM from Mark Skousen, a stock picker with a decent history of good picks. Here is the link:
I researched this by stock gumshoe and determined that the object of Skousen's pitch is Cubist. This would be because Cubisin has shown some encouraging results in combating MRSA. The stimulus to Skousen's prediction would be record earnings to be announced on their report later today.
Cubisin is daptomycin for injection, according to their company web site. At the clinical trials website, I found a Clinical Trial: Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip or Knee Arthroplasty
I bought a few shares just to keep abreast of the opportunity, but would appreciate any comments from longs as to whether the Skousen prediction seems possible.
Interesting to see this thread. We only got the promotion a week or so ago, having owned the stock for years and actually having bought some calls a week or so before. We also thought it sounded like CBST, did a little research, there was another stock that popped up in mention w/Sanofi -- something w/an A? But CBST seemed more like the one he was talking about. DIdn't realize the promo was going out months before it ended up in our email, or know anything about the guy sending it. We wondered if the promo was why we'd seen the pick up in volume lately, but obviously that wouldn't be the case if it's been out for months.
What about the bio-mimic POLYMEDIX, that is currently in Phase 2 trials to do exactly what "your baby" is doing. Except, this one's particular mechanism of action is resistant to any change the bacterium can throw at it.
It attachs itself to gram negative type bacterial membranes and pokes a hole in it. Good bye cytoplasm and hello death to all MRSA type strians.
Hide and watch folks, this can be a live changer. Check it out. PYMX.OB
Good luck with yours for now,
I long ago concluded that Skousen doesn't possess any special prophetic capability, though he's certainly good at selling his own newsletters.
If Skousen claims that a company is going to soon release positive results from a clinical trial, I'd tend to be highly skeptical of such a claim. Clinical trials are conducted under very strict double-blind rules and protocols. There's no way that Skousen can know what the results will be before they've been released. Furthermore, promising drugs often fail spectacularly in their clinical trials.
I'm looking into buying shares of Cubist, but Skousen's apparent pitch (if this is indeed the company he's talking about) is not going to sway my thinking one way or the other.
I subscribed to Skousens' news letter a couple of times. He does a nice selling job but never lived up to his promotions. Many times his suggestions were after most of the good moves had taken place.
How do you know that Skousen is talking about CBST ?
What if he is talking about Forest Laboratories FRX; they also had an anti- MRSA drug approved on Oct. 29, I think ...
And FRX on Jan 18 reported earnings of $ 1.34 for the quarter, which is hugely above the 0.99 estimate ...
Did you not read any of my above posts?! How about this link?
Do you need another...........http://www.marketwatch.com/story/gold-bug-plays-with-stocks-real-estate-2010-11-22?rss=1
Thanks for clarifying this licensing arrangement. I saw the world map as part of the Cubist earnings report and wondered why these other drug companies were shown posted in other countries. I would assume that Cubist gets a commission for each sale?